Основная статистика
| CIK | 1783328 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to TScan Therapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2025 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2025 |
Exhibit 99.1 TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTH |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN THER |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2025 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2025 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| May 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permit |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2025 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 6, 2025 |
Exhibit 99.1 TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market A |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN THE |
|
| March 12, 2025 |
TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 March 12, 2025 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-285570) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities A |
|
| March 5, 2025 |
Exhibit 10.9 830 WINTER STREET WALTHAM, MASSACHUSETTS (the “Building”) SECOND AMENDMENT (“Second Amendment”) EXECUTION DATE: October 28, 2024 (the “Execution Date”) LANDLORD: PPF OFF 828-830 Winter Street LLC, a Delaware limited liability company TENANT: TScan Therapeutics, Inc., a Delaware corporation EXISTING PREMISES: Approximately 25,472 rentable square feet of space in the Building, consistin |
|
| March 5, 2025 |
EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE TScan Therapeutics, Inc. |
|
| March 5, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) TScan Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.000 |
|
| March 5, 2025 |
List of Subsidiaries of Registrant. Exhibit 21 Subsidiaries Subsidiary Jurisdiction of Incorporation or Organization TScan Securities Corporation Massachusetts |
|
| March 5, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 5, 2025 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| March 5, 2025 |
Power of Attorney (included on signature page). As filed with the Securities and Exchange Commission on March 5, 2025 Registration No. |
|
| March 5, 2025 |
As filed with the Securities and Exchange Commission on March 5, 2025 S-3 As filed with the Securities and Exchange Commission on March 5, 2025 Registration No. |
|
| March 5, 2025 |
Form of Senior Indenture between Registrant and one or more trustees to be named. EX-4.3 Exhibit 4.3 TSCAN THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’ |
|
| March 5, 2025 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named. Exhibit 4.4 TSCAN THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Ce |
|
| March 5, 2025 |
Exhibit 19 Insider Trading Policy Table of Contents Page Introduction 1 A. Legal Prohibitions on Insider Trading 1 B. Detection and Prosecution of Insider Trading 1 C. Penalties for Violation of Insider Trading Laws and This Policy 2 D. Compliance Officer 2 E. Reporting Violations 3 F. Personal responsibility 3 Persons and Transactions Covered by This Policy 4 A. Persons Covered by This Policy 4 B |
|
| March 5, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-406 |
|
| March 5, 2025 |
Exhibit 99.1 TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program; TSC-202-A0201 targeting MAGE-A4 on HLA-A*02:01 Closed $30 million registered direct offer |
|
| February 14, 2025 |
EX-1 2 jfa.htm EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Voting Common Stock of TScan Therapeutics, Inc., dated as of February 14, 2025, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provi |
|
| December 26, 2024 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 26, 2024, by and TScan Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser”). RECITALS WHEREAS, subject to the terms and conditions set forth in this Agr |
|
| December 26, 2024 |
Pre-Funded Warrants to Purchase 7,500,000 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268260 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 16, 2023) Pre-Funded Warrants to Purchase 7,500,000 Shares of Common Stock We are offering pre-funded warrants to purchase 7,500,000 shares of voting common stock, in a registered direct offering to a limited number of institutional investors purchaser pursuant to thi |
|
| December 26, 2024 |
Exhibit 4.1 TSCAN THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [*] (subject to adjustment) Warrant No.[*] Original Issue Date: December [*], 2024 TScan Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [*] or its registered |
|
| December 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 26, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissi |
|
| December 23, 2024 |
Exhibit 10.1 [Certain portions of this exhibit have been excluded because they are not material and are the type that the registrant treats as private or confidential.] LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY (“Bank”) and TSCAN THERAPEUTICS, INC., |
|
| December 23, 2024 |
Exhibit 99.1 TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 WALTHAM, Mass., December 23, 2024 — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the developme |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation or organi |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) December 9, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissio |
|
| December 10, 2024 |
KOL Event December 10, 2024 Exhibit 99.2 Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Tscan Therapeutics, Inc. (the “Company” or “TScan”)’s plans, progress, and timing re |
|
| December 10, 2024 |
Exhibit 99.1 TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting toxicities observed |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 15, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation or organi |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga107422tcrx11142024.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, $0. |
|
| November 14, 2024 |
TCRX / TScan Therapeutics, Inc. / K2 HealthVentures Equity Trust LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, $0.0001 par value per share (Title of Class of Securities) 89854M101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| November 14, 2024 |
TCRX / TScan Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2024 |
Exhibit 99.1 TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10th at 8:00 a.m. ET to discuss clinical updates from the ALL |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissi |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) October 28, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissio |
|
| August 12, 2024 |
Employment Agreement, dated April 4, 2024 by and between Registrant and Chrystal Louis. Exhibit 10.1 Employment Agreement THIS AGREEMENT (the “Agreement”) is entered into by and between Chrystal Louis (the “Executive” or “you”) and TScan Therapeutics, Inc. (the “Company”), a Delaware corporation, as of the date all parties hereto have signed the Agreement. 1. Duties and Scope of Employment. (a) Position. The Company agrees to employ the Executive in the position of Chief Medical Offi |
|
| August 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN THER |
|
| August 12, 2024 |
Exhibit 99.1 TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report ini |
|
| June 14, 2024 |
As filed with the Securities and Exchange Commission on June 14, 2024 As filed with the Securities and Exchange Commission on June 14, 2024 Registration No. |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 12, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| June 14, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) TScan Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.000 |
|
| June 14, 2024 |
Amended and Restated TScan Therapeutic, Inc. 2021 Equity Incentive Plan EX-10.1 Exhibit 10.1 TSCAN THERAPEUTICS, INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN Adopted on April 22, 2021 Amended and Restated on June 12, 2024 TSCAN THERAPEUTICS, INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately, although no Awards may be granted prior to the IPO Date. The purpose of the Plan is |
|
| June 14, 2024 |
EX-99.1 Exhibit 99.1 TScan Therapeutics Announces Updates to its Board of Directors Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role of Chair WALTHAM, Mass., June 14, 2024 — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical co |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN THE |
|
| May 13, 2024 |
Exhibit 99.1 TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no detectable disease, with a median follow-up of >10 months Closed upsized underwritten public off |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 13, 2024 |
Employment Agreement, dated January 29, 2024, by and between the Registrant and Jason A. Amello. Exhibit 10.1 Employment Agreement This Agreement (the “Agreement”) is entered into by and between Jason A. Amello (the “Executive” or “you”) and TScan Therapeutics, Inc. (the “Company”), a Delaware corporation, as of the date all parties hereto have signed the Agreement. 1. Duties and Scope of Employment. (a) Position. The Company agrees to employ the Executive in the position of Chief Financial O |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| April 30, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 29, 2024 |
EX-99.1 2 exhibit99-1.htm Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of April 29, 2024, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a stat |
|
| April 29, 2024 |
TCRX / TScan Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock (Title of Class of Securities) 89854M101 (CUSIP Number) April 19, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| April 23, 2024 |
TCRX / TScan Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment SC 13D/A 1 tm2412362d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* TScan Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities |
|
| April 18, 2024 |
2,472,581 Shares of Common Stock Pre-Funded Warrants to Purchase 18,577,419 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277699 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 12, 2024) 2,472,581 Shares of Common Stock Pre-Funded Warrants to Purchase 18,577,419 Shares of Common Stock We are offering 2,472,581 shares of our voting common stock and, in lieu of voting common stock to certain investors that so choose, pre-funded warrants to p |
|
| April 17, 2024 |
Free Writing Prospectus Filed Pursuant to Rule 433 To Prospectus dated April 12, 2024 Preliminary Prospectus Supplement dated April 16, 2024 Registration Statement File No. |
|
| April 17, 2024 |
Exhibit 4.1 TSCAN THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [*] (subject to adjustment) Warrant No.[*] Original Issue Date: April [*], 2024 TScan Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [*] or its registered ass |
|
| April 17, 2024 |
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering Exhibit 99.2 TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritte |
|
| April 17, 2024 |
TScan Therapeutics Announces Launch of $125 million Proposed Public Offering Exhibit 99.1 TScan Therapeutics Announces Launch of $125 million Proposed Public Offering WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an unde |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 16, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission |
|
| April 17, 2024 |
Exhibit 1.1 Execution Version 2,472,581 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) PRE-FUNDED WARRANTS TO PURCHASE 18,577,419 SHARES OF COMMON STOCK TScan Therapeutics, Inc. UNDERWRITING AGREEMENT April 16, 2024 April 16, 2024 Morgan Stanley & Co. LLC TD Securities (USA) LLC as Representatives of the several Underwriters listed in Schedule II hereto c/o Morgan Stanley & Co. LLC 1585 Broa |
|
| April 16, 2024 |
EX-99.2 Exhibit 99.2 TScan Therapeutics April 2024 Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking TScan’s plans relating to developing and commercializing its TCR-T therapy statements within the meaning of the Private Securities Litigation Reform Act of candidates, if approved, including sales strategy; estimates of the size of |
|
| April 16, 2024 |
$125,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277699 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus a |
|
| April 16, 2024 |
EX-99.1 Exhibit 99.1 TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex therapy Patients identified across all six TCR-T cohorts in solid tumor program with dosi |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 16, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission |
|
| April 10, 2024 |
TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 April 10, 2024 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-277699) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities A |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Num |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 8, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| April 8, 2024 |
Exhibit 99.1 TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development WALTHAM, Mass., April 8, 2024 — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the developme |
|
| March 6, 2024 |
Form of Senior Indenture between Registrant and one or more trustees to be named. Exhibit 4.4 TSCAN THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certi |
|
| March 6, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) TScan Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.000 |
|
| March 6, 2024 |
As filed with the Securities and Exchange Commission on March 6, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 6, 2024 Registration No. |
|
| March 6, 2024 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named. Exhibit 4.5 TSCAN THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Ce |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 6, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| March 6, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-406 |
|
| March 6, 2024 |
Exhibit 97 TSCan therapeutics, Inc. COMPENSATION RECOVERY POLICY Adopted as of September 21, 2023 TScan Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Person |
|
| March 6, 2024 |
Power of Attorney (included on signature page). S-8 As filed with the Securities and Exchange Commission on March 6, 2024 Registration No. |
|
| March 6, 2024 |
Employment Agreement, dated July 28, 2021, by and between the Registrant and Zoran Zdraveski. Exhibit 10.17 EMPLOYMENT AGREEMENT THIS AGREEMENT (the “Agreement”) is entered into by and between ZORAN ZDRAVESKI (the “Executive” or “you”) and TSCAN THERAPEUTICS, INC., a Delaware corporation (the “Company”), as of the date all parties hereto have signed the Agreement. 1. Duties and Scope of Employment. (a) Position. For the term of his employment under this Agreement (the “Employment”), the Co |
|
| March 6, 2024 |
List of Subsidiaries of Registrant. Exhibit 21 Subsidiaries Subsidiary Jurisdiction of Incorporation or Organization TScan Securities Corporation Massachusetts |
|
| March 6, 2024 |
Employment Agreement, dated May 25, 2023, by and between the Registrant and Gavin MacBeath, Ph.D. Exhibit 10.14 Employment Agreement This Agreement (the “Agreement”), effective as of May 25, 2023, is entered into by and between GAVIN MACBEATH (the “Executive” or “you”) and TScan Therapeutics, Inc. (the “Company”), a Delaware corporation and replaces and supersedes all other employment agreements and understandings between the Executive and Company except as otherwise set forth herein. 1. Dutie |
|
| March 6, 2024 |
Exhibit 99.1 TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are relapse-free and show complete donor chimerism Announced the clearance of two add |
|
| March 6, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE TScan Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities (Form S-3) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| February 14, 2024 |
TCRX / TScan Therapeutics, Inc. / K2 HealthVentures Equity Trust LLC - SC 13G/A Passive Investment SC 13G/A 1 ef20021589sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, $0.0001 par value per share (Title of Class of Securities) 89854M101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Sta |
|
| February 9, 2024 |
TCRX / TScan Therapeutics, Inc. / GV 2017, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 8, 2024 |
Exhibit 1 – Joint Filing Agreement pursuant to Rule 13d-1(k)(1) EX-99.1 2 tm245444d1ex-1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned parties hereby agree that this Amendment No. 1 to the Statement of Beneficial Ownership on Schedule 13G filed herewith by the undersigned parties, relating to the common stock, par value $0.0001 per share of TScan Therapeutics, Inc., is being filed jointly with the Securities and Exchange Commission pursuant to |
|
| February 8, 2024 |
TCRX / TScan Therapeutics, Inc. / Pitango HealthTech Fund I, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm245444d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TScan Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP Number) Ofira Kadmor Senior VP Finance Pitango Venture Capital 11 HaMenofim St. |
|
| February 7, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the ru |
|
| January 29, 2024 |
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer Exhibit 99.1 TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer WALTHAM, Mass., January 29, 2024 — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Jas |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2024 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissio |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 9, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissio |
|
| December 11, 2023 |
TScan Therapeutics KOL event: Dec. 11, 2023 Exhibit 99.2 Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company’s plans, progress, and timing relating to the Company’s |
|
| December 11, 2023 |
Exhibit 99.1 TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical intervention No patient-derived hematopo |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 6, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissio |
|
| December 7, 2023 |
EX-99.1 Exhibit 99.1 TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations WALTHAM, Mass., Dec 7, 2023 — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, to |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2023 |
Exhibit 99.1 TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Company to present poster on initial data from heme malignancies Phase 1 trial at the 65th ASH Annual Meeting and Exposition; Company to host virtual KOL event on Monday, December 11, 2023, at 8:00 a.m. ET Announced recent FDA clearance of IND for TSC-203-A0201 targeting PRAME Presented six p |
|
| November 9, 2023 |
Exhibit 10.1 830 WINTER STREET WALTHAM, MASSACHUSETTS (the “Building”) FIRST AMENDMENT (“First Amendment”) EXECUTION DATE: November 8, 2023 (the “Execution Date”) LANDLORD: PPF OFF 828-830 Winter Street LLC, a Delaware limited liability company TENANT: TScan Therapeutics, Inc., a Delaware corporation PREMISES: Approximately 25,472 rentable square feet of space in the Building, consisting of approx |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN |
|
| August 10, 2023 |
Exhibit 99.1 TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Presented preliminary Phase 1 clinical data from heme malignancies trial at the ASGCT 26th Annual Meeting; expect to reach recommended Phase 2 dose for two TCR-T therapy product candidates and report interim data by year-end 2023 Announced FDA clearance of fourth IND for solid tumor program |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN THER |
|
| August 10, 2023 |
Exhibit 10.1 CONFIDENTIAL FOR DISCUSSION PURPOSES ONLY EXECUTION VERSION CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Research Collaboration and License Agreement This Research Collaboration and License Agreement (“Agreement”) is made and |
|
| August 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 20, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| June 29, 2023 |
TScan Therapeutics Announces Transition of Chief Financial Officer EX-99.1 Exhibit 99.1 TScan Therapeutics Announces Transition of Chief Financial Officer WALTHAM, Mass., June 29, 2023 — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-Ts) for the treatment of patients with cancer, today announced that its Chief Financial Officer, Brian M. Silve |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 27, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| June 16, 2023 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) TScan Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Commo |
|
| June 16, 2023 |
EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO THE TSCAN THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN WHEREAS, TScan Therapeutics, Inc. (the “Company”) maintains the TScan Therapeutics, Inc. 2021 Equity Incentive Plan (the “Plan”), which was previously adopted by the Board of Directors of the Company (the “Board”) and approved by the stockholders of the Company; WHEREAS, the Board desires to amend the P |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 16, 2023 S-8 As filed with the Securities and Exchange Commission on June 16, 2023 Registration No. |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 13, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| June 12, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP Number) May 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| June 5, 2023 |
TCRX / Tscan Therapeutics Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, $0.0001 par value per share (Title of Class of Securities) 89854M101 (CUSIP |
|
| June 5, 2023 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated June 5, 2023 with respect to the Voting Common Stock, $0.0001 par value per share, of TScan Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordan |
|
| June 5, 2023 |
TCRX / Tscan Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP Number) May 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| June 2, 2023 |
TCRX / Tscan Therapeutics Inc / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| June 2, 2023 |
EX-99 2 p23-1699exhibit99.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agree |
|
| June 2, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, $0.0001 par value per share (Title of Class of Securities) 89854M101 (CUSIP Number) May 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| June 2, 2023 |
DEFA14A 1 d501127ddefa14a.htm DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Co |
|
| May 31, 2023 |
EX-4.1 Exhibit 4.1 TSCAN THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2023 TScan Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assig |
|
| May 31, 2023 |
Exhibit 4.1 to the Issuer’s Current Report on Form 8-K, filed with the SEC on May 31, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 31, 2023 |
TScan Therapeutics Announces Pricing of $140 Million Public Offering EX-99.2 Exhibit 99.2 TScan Therapeutics Announces Pricing of $140 Million Public Offering WALTHAM, Mass., May 26, 2023 — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering o |
|
| May 31, 2023 |
TScan Therapeutics Announces Launch of Proposed Public Offering EX-99.1 Exhibit 99.1 TScan Therapeutics Announces Launch of Proposed Public Offering WALTHAM, Mass., May 25, 2023 — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 24, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 31, 2023 |
Underwriting Agreement dated May 25, 2023. EX-1.1 Exhibit 1.1 EXECUTION VERSION 22,989,474 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) PRE-FUNDED WARRANTS TO PURCHASE 47,010,526 SHARES OF COMMON STOCK TScan Therapeutics, Inc. UNDERWRITING AGREEMENT May 25, 2023 May 25, 2023 Morgan Stanley & Co. LLC Wedbush Securities Inc. as Representatives of the several Underwriters listed in Schedule II hereto c/o Morgan Stanley & Co. LLC 1585 |
|
| May 31, 2023 |
EX-99.1 Exhibit 99.1 TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors WALTHAM, Mass., May 24 , 2023 — TScan Therapeutics, Inc. (Nasdaq: TCRX) (TScan), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today |
|
| May 30, 2023 |
22,989,474 Shares of Common Stock Pre-Funded Warrants to Purchase 47,010,526 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268260 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 16, 2023) 22,989,474 Shares of Common Stock Pre-Funded Warrants to Purchase 47,010,526 Shares of Common Stock We are offering 22,989,474 shares of our voting common stock and pre-funded warrants to purchase 47,010,526 shares of voting common stock in this offering. Our voti |
|
| May 26, 2023 |
FWP Free Writing Prospectus Filed Pursuant to Rule 433 To Prospectus dated May 16, 2023 Preliminary Prospectus Supplement dated May 25, 2023 Registration Statement File No. |
|
| May 25, 2023 |
Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-268260 This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospe |
|
| May 17, 2023 |
EX-99.1 Exhibit 99.1 TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation Company to host a virtual KOL event featuring Monzr M. Al Malki, M.D., to discuss highlights from the me |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 17, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 16, 2023 |
As filed with the Securities and Exchange Commission on May 15, 2023 S-3/A As filed with the Securities and Exchange Commission on May 15, 2023 Registration No. |
|
| May 16, 2023 |
As filed with the Securities and Exchange Commission on May 15, 2023 S-3/A As filed with the Securities and Exchange Commission on May 15, 2023 Registration No. |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 16, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 16, 2023 |
Exhibit 1.1 TSCAN THERAPEUTICS, INC. Common Stock Sales Agreement May 16, 2023 Wedbush Securities Inc. 1000 Wilshire Blvd. Los Angeles, CA 90017 Ladies and Gentlemen: TScan Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Wedbush Securities Inc. (“Wedbush”), as follows: 1. Issuance and Sale of Placement Shares. The Company agrees that, from |
|
| May 16, 2023 |
TSCAN THERAPEUTICS, INC. May 16, 2023 TSCAN THERAPEUTICS, INC. May 16, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Re: TScan Therapeutics, Inc. (CIK 0001783328) Request to Withdraw Pre-Effective Amendment No. 1 to Registration Statement (Reg No. 333-268260) on Form S-3 (Accession No. 0001193125-23-145261) Ladies and Gentlemen: Pursuant to Rule 477 promulga |
|
| May 16, 2023 |
Up to $75,000,000 Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-268260 PROSPECTUS SUPPLEMENT (To Prospectus dated May 16, 2023) Up to $75,000,000 Common Stock We have entered into a sales agreement, dated as of May 16, 2023, or Sales Agreement, with Wedbush Securities Inc., or Wedbush, relating to shares of our voting common stock, par value $0.0001 per share, offered by this prospectus su |
|
| May 16, 2023 |
As filed with the Securities and Exchange Commission on May 15, 2023 S-3/A As filed with the Securities and Exchange Commission on May 15, 2023 Registration No. |
|
| May 15, 2023 |
TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 CORRESP TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 May 15, 2023 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-268260) Ladies and Gentlemen: Pursuant to Rule 461 under the Securi |
|
| May 15, 2023 |
TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 May 15, 2023 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-268261) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act |
|
| May 10, 2023 |
EX-99.1 TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Entered into partnership with Amgen to identify novel targets in Crohn’s disease; TScan to receive $30 million upfront Enrolled patients in all three arms of Phase 1 hematologic malignancies study; TSC-101 progressing to second dose level Announced upcoming trial-in-progress poster presentation on |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN THE |
|
| May 10, 2023 |
TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 CORRESP TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 May 10, 2023 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-268261) Ladies and Gentlemen: Pursuant to Rule 461 under the Securi |
|
| May 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 10, 2023 |
TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 CORRESP TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 May 10, 2023 Via EDGAR Transmission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 (File No. 333-268260) Ladies and Gentlemen: Pursuant to Rule 461 under the Securi |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2023 |
EX-99.1 Exhibit 99.1 News Release AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN’S DISEASE Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million T |
|
| April 25, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 25, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 10, 2023 |
EX-99.1 Exhibit 99.1 TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors Deepens the Board’s clinical oncology and commercialization expertise as programs for hematologic malignancies and solid tumors advance Company also announces key leadership promotions WALTHAM, Mass., April 10, 2023 — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmac |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 6, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 27, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission |
|
| March 31, 2023 |
EX-99.1 Exhibit 99.1 TSCAN THERAPEUTICS ANNOUNCES CEO TRANSITION David Southwell Steps Down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to Serve as Acting CEO Company Reaffirms Previously Disclosed Milestones and Cash Runway; Provides Clinical Program Update WALTHAM, Mass., March 31 2023 — TScan Therapeutics, Inc. (Nasdaq: TCRX) [“TScan” or “The Company”], a clinical-stage biop |
|
| March 8, 2023 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) TScan Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Commo |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40603 TSCAN THERAPEUT |
|
| March 8, 2023 |
Exhibit 99.1 TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones Phase 1 umbrella trial for TSC-100 and TSC-101 in hematologic malignancies on track to enroll patients into each of the three study arms and provide a clinical update including safety and biomarker data by mid-year 2023 Clearance of primary IND (T-Plex) in addition to two |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 08, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission |
|
| March 8, 2023 |
As filed with the Securities and Exchange Commission on March 8, 2023 As filed with the Securities and Exchange Commission on March 8, 2023 Registration No. |
|
| February 14, 2023 |
SC 13G/A 1 p23-0185sc13ga.htm TSCAN THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This S |
|
| January 23, 2023 |
Exhibit 99.1 TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies based on target and HLA expression INDs for TSC-204-A0201 and TSC-204-C0702 introduce the first two TCRs into TScan’s Im |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2023 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE TScan Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities (Form S-3) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry |
|
| November 9, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE TScan Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities (Form S-3) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| November 9, 2022 |
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Four sites for hematologic malignancies program open and enrolling patients Completed pre-IND meeting with the FDA for solid tumor program; virtual investor event Monday, November 14, at 5:00 PM ET to highlight clinical trial design Ended quarter with cash and cash equivalents of $137. |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN |
|
| November 9, 2022 |
As filed with the Securities and Exchange Commission on November 9, 2022 Table of Contents As filed with the Securities and Exchange Commission on November 9, 2022 Registration No. |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 TSCAN THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40603 82-5282075 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 9, 2022 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named. Exhibit 4.5 TSCAN THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Ce |
|
| November 9, 2022 |
Power of Attorney (included in the signature pages to the Registration Statement) Table of Contents As filed with the Securities and Exchange Commission on November 9, 2022 Registration No. |
|
| November 9, 2022 |
Form of Senior Indenture between Registrant and one or more trustees to be named. Exhibit 4.4 TSCAN THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certi |
|
| September 30, 2022 |
TCRX / TScan Therapeutics, Inc. / K2 HealthVentures Equity Trust LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, $0.0001 par value per share (Title of Class of Securities) 89854M101 (CUSIP Number) September 9, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commis |
|
| September 12, 2022 |
Exhibit 10.1 Execution Version LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this ?Agreement?) dated as of September 9, 2022 (the ?Closing Date?) is entered into among TSCAN THERAPEUTICS, INC., a Delaware corporation (?Borrower Representative?), and each other Person party hereto as a borrower from time to |
|
| September 12, 2022 |
Exhibit 99.1 TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures Financing supports management?s focus on clinical execution and advancing its ImmunoBank Initial $30 million tranche extends cash runway into the second quarter of 2024 WALTHAM, Mass., September 12, 2022 ? TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company |
|
| August 15, 2022 |
TCRX / TScan Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TSCAN THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP Number) August 15, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. |
|
| August 10, 2022 |
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings anticipated by year-end 2022 Appointment of Debora Barton, M. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissio |
|
| August 10, 2022 |
EX-10.1 2 tcrx-ex101.htm EX-10.1 Exhibit 10.1 C Form Employment Agreement THIS AGREEMENT (the “Agreement”) is entered into by and between Debora Barton (the “Executive” or “you”) and TScan Therapeutics, Inc., a Delaware corporation (the “Company”), as of the date all parties hereto have signed the Agreement. Duties and Scope of Employment. (a) Position. For the term of his or her employment under |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| May 31, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission F |
|
| May 31, 2022 |
Exhibit 99.1 TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies Study start-up activities now ongoing for all three arms of the Phase 1 umbrella trial of TSC-100 and TSC-101 WALTHAM, Mass., May 31, 2022 ? TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the develo |
|
| May 12, 2022 |
TCRX / TScan Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 9, 2022 |
Exhibit 99.1 TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones Preclinical data to be presented at the American Society of Gene & Cell Therapy 25th Annual Meeting; virtual KOL event following the conference Phase 1 umbrella trial for leukemia program on track to initiate in the first half of 2022 Ended the first quarter with cash and cash equivalen |
|
| April 21, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| March 9, 2022 |
As filed with the Securities and Exchange Commission on March 9, 2022 As filed with the Securities and Exchange Commission on March 9, 2022 Registration No. |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40603 TSCAN THERAPEUT |
|
| March 9, 2022 |
Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the securities of TScan Therapeutics, Inc. (?us,? ?our,? ?we? or the ?Company?) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), is intended as a summary of the material terms of our amended and restate |
|
| March 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 9, 2022 |
Exhibit 99.1 TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies Phase 1 umbrella trial for liquid tumor program to initiate in H1 2022; preliminary data expected in H2 2022 Two INDs for TSC-200 series anticipated by year end Strong balance sheet with cash and cash equ |
|
| March 9, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) TScan Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.000 |
|
| February 14, 2022 |
TCRX / TScan Therapeutics, Inc. / Deer IX & Co. Ltd. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* TScan Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 89854M101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 14, 2022 |
EXHIBIT 1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. |
|
| February 14, 2022 |
TCRX / TScan Therapeutics, Inc. / Pitango HealthTech Fund I, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TScan Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP Number) Ofira Kadmor Senior VP Finance Pitango Venture Capital 11 HaMenofim St. Bldg. B Herzliya 4672562, Israel Tel +972-9 |
|
| February 14, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned parties hereby agree that this Statement on Schedule 13G filed herewith, and any amendments thereto filed hereafter by any of the undersigned parties, relating to the Common Stock, par value $0. |
|
| February 14, 2022 |
Exhibit 2 Members of Group Deer IX & Co. Ltd. Deer IX & Co. L.P. Bessemer Venture Partners IX L.P. Bessemer Venture Partners IX Institutional L.P. |
|
| February 14, 2022 |
EXHIBIT A Agreement of Joint Filing The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Voting Common Stock of TScan Therapeutics, Inc. |
|
| February 14, 2022 |
TCRX / TScan Therapeutics, Inc. / HILLHOUSE CAPITAL MANAGEMENT, LTD. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| February 14, 2022 |
TCRX / TScan Therapeutics, Inc. / GV 2017, L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TScan Therapeutics, Inc. (Name of Issuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 10, 2022 |
TCRX / TScan Therapeutics, Inc. / Longwood Fund IV, L.P. - SC 13G Passive Investment SC 13G 1 d317942dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TSCAN THERAPEUTICS, INC. (Name of Issuer) Voting Common Stock, $0.0001 par value per share (Title of Class of Securities) 89854M101 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) |
|
| February 10, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| January 24, 2022 |
Exhibit 99.1 TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies - Phase 1 trial of TSC-100 expected to initiate in the first half of 2022 ? - IND for TSC-101 on hold pending additional assessment of the risk of off-tumor reactivity ? WALTHAM, Mass., Jan. 24, 2022 ? TScan Therapeutics, Inc. (Nasdaq: TCRX), a b |
|
| January 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2022 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissi |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissi |
|
| December 2, 2021 |
Lease, by and between TScan Therapeutics, Inc. and BXP Waltham Woods LLC, dated November 29, 2021 Exhibit 10.1 WALTHAM WOODS CORPORATE CENTER 880 WINTER STREET WALTHAM, MASSACHUSETTS Lease Dated November 29, 2021 THIS INSTRUMENT IS AN INDENTURE OF LEASE in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in a certain building (the ?Building?) known as, and with an address at, 880 Winter Street, Waltham, Massachusetts 02451. The parties to this Ind |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. |
|
| November 10, 2021 |
Employment Agreement, dated July 28, 2021, by and between the Registrant and Zoran Zdraveski. Exhibit 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT (the ?Agreement?) is entered into by and between ZORAN ZDRAVESKI (the ?Executive? or ?you?) and TSCAN THERAPEUTICS, INC., a Delaware corporation (the ?Company?), as of the date all parties hereto have signed the Agreement. 1. Duties and Scope of Employment. (a) Position. For the term of his employment under this Agreement (the ?Employment?), the Com |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commiss |
|
| November 10, 2021 |
EX-99.1 TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates TSC-100 and TSC-101 Lead TCR Identified for TSC-200 Solid-tumor Program Targeting HPV16; TCR Advancing into IND-Enabling Activities with IND Submission Planned for Second Half of 2022 New Solid |
|
| August 19, 2021 |
Exhibit 99.1 TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates, TSC-100 and TSC-101 WALTHAM, Mass., August 19, 2021 - TScan Therapeuti |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40603 TSCAN THERAPEUTICS, INC. |
|
| August 19, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporation) (Commissio |
|
| July 28, 2021 |
TCRX / TScan Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TScan Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 89854M101 (CUSIP Number) July 20, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| July 22, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D (and any amendments thereto) need be filed with respect to the beneficial ownership by each of the undersigned of securities of TScan Therapeutics, Inc.. This Agreement may be |
|
| July 22, 2021 |
TCRX / TScan Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| July 22, 2021 |
Exhibit 99.3 July 8, 2021 Morgan Stanley & Co. LLC Jefferies LLC Cowen and Company, LLC Barclays Capital Inc. c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 Ladies and Gentle |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2021 (July 15, 2021) TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40603 82-5282075 (State or other jurisdiction of incorporati |
|
| July 20, 2021 |
Exhibit 3.1 TScan Therapeutics, Inc. Amended and Restated Certificate of Incorporation TScan Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is TScan Therapeutics, Inc., and that the corporation was originally incorporated pursuant to the General Corporation Law of the State of Delaware on |
|
| July 20, 2021 |
Exhibit 3.2 TScan Therapeutics, Inc. Amended and Restated Bylaws (amended and restated on April 22, 2021 and effective as of the closing of this corporation?s initial public offering) Table of Contents Page Article I Stockholders 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 2 1.6 Quorum 2 1.7 Adjournments 3 1.8 Voting and Proxies 3 |
|
| July 19, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-255491 Registration No. 333-257938 PROSPECTUS 6,666,667 Shares COMMON STOCK TScan Therapeutics, Inc. is offering 6,666,667 shares of its common stock. This is our initial public offering and no public market currently exists for our shares of common stock. The initial public offering price is $15.00 per share. Our common stock |
|
| July 16, 2021 |
2021 Employee Stock Purchase Plan. Exhibit 99.4 TSCAN THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN (AS ADOPTED ON APRIL 22, 2021) TSCAN THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN SECTION 1. PURPOSE OF THE PLAN. The Board adopted the Plan to become effective immediately, although no shares may be issued hereunder prior to the IPO Date. The purpose of the Plan is to provide Eligible Employees with an opportunity to |
|
| July 16, 2021 |
Issuer Free Writing Prospectus dated July 15, 2021 Filed Pursuant to Rule 433 Relating to Preliminary Prospectus dated July 12, 2021 Registration Statement No. |
|
| July 16, 2021 |
2021 Equity Incentive Plan and forms of agreements thereunder. Exhibit 99.3 TSCAN THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN (AS ADOPTED ON APRIL 22, 2021) TSCAN THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately, although no Awards may be granted prior to the IPO Date. The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder val |
|
| July 16, 2021 |
As filed with the Securities and Exchange Commission on July 16, 2021 As filed with the Securities and Exchange Commission on July 16, 2021 Registration No. |
|
| July 15, 2021 |
As filed with the Securities and Exchange Commission on July 15, 2021. S-1MEF 1 d107876ds1mef.htm S-1MEF As filed with the Securities and Exchange Commission on July 15, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 TSCAN THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2836 82-5282075 (State or other jurisdiction of |
|
| July 14, 2021 |
SILICON VALLEY ANN ARBOR BEIJING BOSTON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO SINGAPORE July 14, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| July 13, 2021 |
July 13, 2021 VIA EDGAR U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park and Tim Buchmiller Re: TScan Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 (File No. 333-255491) Ladies and Gentlemen: In connection with the above-captioned Registratio |
|
| July 13, 2021 |
July 13, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jane Park Tim Buchmiller Re: TScan Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-255491 Request for Acceleration of Effective Date Requested Date: Thursday, July 15, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies and Gent |
|
| July 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 82-5282075 (State of incorporation or organization) (I.R.S. Employer Identification No.) 830 Winter Street, |
|
| July 12, 2021 |
S-1/A 1 d107876ds1a.htm S-1/A Table of Contents As filed with the Securities and Exchange Commission on July 12, 2021. Registration No. 333-255491 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 TSCAN THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2836 82- |
|
| May 14, 2021 |
As filed with the Securities and Exchange Commission on May 14, 2021. Table of Contents As filed with the Securities and Exchange Commission on May 14, 2021. |
|
| May 14, 2021 |
Exhibit 3.1 Execution Version AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TSCAN THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) TScan Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY |
|
| May 5, 2021 |
As filed with the Securities and Exchange Commission on May 5, 2021. Registration No. 333-255491 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No 2 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 TSCAN THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2836 82-5282075 (State or other jurisdiction of incorporati |
|
| May 5, 2021 |
SILICON VALLEY ANN ARBOR BEIJING BOSTON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO SINGAPORE May 5, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| May 5, 2021 |
Employment Agreement, dated May 4, 2021, by and between the Registrant and Brian Silver. Exhibit 10.19 CFO EMPLOYMENT AGREEMENT THIS AGREEMENT (the “Agreement”) is entered into by and between BRIAN SILVER (the “Executive” or “you”) and TSCAN THERAPEUTICS, INC. (the “Company”), a Delaware corporation and replaces and supersedes the employment agreement between the Executive and Company, dated February 1, 2021 (as amended, the “Prior Agreement”). 1. Duties and Scope of Employment. (a) P |
|
| May 5, 2021 |
Exhibit 10.3 TSCAN THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN (As Adopted on April 22, 2021) TSCAN THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately, although no Awards may be granted prior to the IPO Date. The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder val |
|
| May 5, 2021 |
Exhibit 3.2 TScan Therapeutics, Inc. Amended and Restated Certificate of Incorporation TScan Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is TScan Therapeutics, Inc., and that the corporation was originally incorporated pursuant to the General Corporation Law of the State of Delaware on |
|
| April 30, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 [ ] Shares TScan Therapeutics, Inc. COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT [ ], 2021 [ ], 2021 Morgan Stanley & Co. LLC Jefferies LLC Cowen and Company, LLC Barclays Capital Inc. as Representatives of the several Underwriters listed in Schedule I hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue Ne |
|
| April 30, 2021 |
*FOIA Confidential Treatment Request* Confidential Treatment Requested by TScan Therapeutics, Inc. |
|
| April 30, 2021 |
2021 Employee Stock Purchase Plan. Exhibit 10.4 TSCAN THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN (AS ADOPTED ON APRIL 22, 2021) TSCAN THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN SECTION 1. PURPOSE OF THE PLAN. The Board adopted the Plan effective as of the IPO Date. The purpose of the Plan is to provide Eligible Employees with an opportunity to increase their proprietary interest in the success of the Company by |
|
| April 30, 2021 |
SILICON VALLEY ANN ARBOR BEIJING BOSTON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO SINGAPORE April 30, 2021 Via EDGAR U. |
|
| April 30, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on April 30, 2021. |
